CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 925 of 1294 entries

View as:

Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00700830 Org: User:

Start: 01/31/08 End: 09/30/09 Due: 09/30/10

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01526980 Org: User:

Start: 05/31/02 End: 11/30/02 Due: 11/30/03

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT02030600 Org: User:

Start: 01/06/14 End: 12/04/15 Due: 12/04/16

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Phase: N/A Priority: Normal

NCT ID: NCT04067999 Org: User:

Start: 08/05/19 End: 07/19/21 Due: 07/19/22

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01520753 Org: User:

Start: 03/31/99 End: 06/30/99 Due: 06/30/00

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01631942 Org: User:

Start: 06/26/12 End: 09/04/12 Due: 09/04/13

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin

Phase: N/A Priority: Normal

NCT ID: NCT00775736 Org: User:

Start: 10/31/08 End: 01/31/11 Due: 01/31/12

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia

Phase: N/A Priority: Normal

NCT ID: NCT00788853 Org: User:

Start: 11/30/08 End: 02/28/09 Due: 02/28/10

Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT01448070 Org: User:

Start: 10/15/02 End: 12/20/02 Due: 12/20/03

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00978627 Org: User:

Start: 08/31/09 End: 05/31/10 Due: 05/31/11

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal

NCT ID: NCT00620282 Org: User:

Start: 02/29/08 End: 05/31/10 Due: 05/31/11

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01006291 Org: User:

Start: 11/30/09 End: 09/30/10 Due: 09/30/11

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Phase: N/A Priority: Normal

NCT ID: NCT03479762 Org: User:

Start: 04/20/18 End: 09/12/22 Due: 09/12/23

Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial

Phase: N/A Priority: Normal

NCT ID: NCT00464971 Org: User:

Start: 01/31/95 End: 11/30/96 Due: 11/30/97

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Phase: N/A Priority: Normal

NCT ID: NCT02255266 Org: User:

Start: 03/26/15 End: 11/16/15 Due: 11/16/16

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal

NCT ID: NCT01950637 Org: User:

Start: 01/31/12 End: 01/31/13 Due: 01/31/14

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01686945 Org: User:

Start: 09/19/12 End: 04/08/13 Due: 04/08/14

Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00564668 Org: User:

Start: 06/19/04 End: 04/12/05 Due: 04/12/06

A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin

Phase: N/A Priority: Normal

NCT ID: NCT02162407 Org: User:

Start: 10/31/99 End: 12/31/99 Due: 12/31/00

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT00333151 Org: User:

Start: 05/31/06 End: 08/31/07 Due: 08/31/08

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01562561 Org: User:

Start: 06/01/01 End: 12/20/02 Due: 12/20/03

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01868568 Org: User:

Start: 04/30/08 End: 08/31/08 Due: 08/31/09

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Phase: N/A Priority: Normal

NCT ID: NCT02005198 Org: User:

Start: 03/31/14 End: 12/31/15 Due: 12/31/16

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT01507311 Org: User:

Start: 09/30/99 End: 12/31/99 Due: 12/31/00

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01916174 Org: User:

Start: 08/31/13 End: 11/30/13 Due: 11/30/14

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes	NCT00700830	Novo Nordisk A/S	user2@example.com	None	2008-01-31	2009-09-30	2010-09-30	-	-	2025-07-14
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes	NCT01526980	Novo Nordisk A/S	user2@example.com	None	2002-05-31	2002-11-30	2003-11-30	-	-	2025-07-14
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes	NCT02030600	Novo Nordisk A/S	user2@example.com	None	2014-01-06	2015-12-04	2016-12-04	-	-	2025-07-14
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice	NCT04067999	Novo Nordisk A/S	user2@example.com	None	2019-08-05	2021-07-19	2022-07-19	-	-	2025-07-14
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes	NCT01520753	Novo Nordisk A/S	user2@example.com	None	1999-03-31	1999-06-30	2000-06-30	-	-	2025-07-14
A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects	NCT01631942	Novo Nordisk A/S	user2@example.com	None	2012-06-26	2012-09-04	2013-09-04	-	-	2025-07-14
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin	NCT00775736	Novo Nordisk A/S	user2@example.com	None	2008-10-31	2011-01-31	2012-01-31	-	-	2025-07-14
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia	NCT00788853	Novo Nordisk A/S	user2@example.com	None	2008-11-30	2009-02-28	2010-02-28	-	-	2025-07-14
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers	NCT01448070	Novo Nordisk A/S	user2@example.com	None	2002-10-15	2002-12-20	2003-12-20	-	-	2025-07-14
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes	NCT00978627	Novo Nordisk A/S	user2@example.com	None	2009-08-31	2010-05-31	2011-05-31	-	-	2025-07-14
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus	NCT00620282	Novo Nordisk A/S	user2@example.com	None	2008-02-29	2010-05-31	2011-05-31	-	-	2025-07-14
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes	NCT01006291	Novo Nordisk A/S	user2@example.com	None	2009-11-30	2010-09-30	2011-09-30	-	-	2025-07-14
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database	NCT03479762	Novo Nordisk A/S	user2@example.com	None	2018-04-20	2022-09-12	2023-09-12	-	-	2025-07-14
Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial	NCT00464971	Novo Nordisk A/S	user2@example.com	None	1995-01-31	1996-11-30	1997-11-30	-	-	2025-07-14
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice	NCT02255266	Novo Nordisk A/S	user2@example.com	None	2015-03-26	2015-11-16	2016-11-16	-	-	2025-07-14
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus	NCT01950637	Novo Nordisk A/S	user2@example.com	None	2012-01-31	2013-01-31	2014-01-31	-	-	2025-07-14
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes	NCT01686945	Novo Nordisk A/S	user2@example.com	None	2012-09-19	2013-04-08	2014-04-08	-	-	2025-07-14
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes	NCT00564668	Novo Nordisk A/S	user2@example.com	None	2004-06-19	2005-04-12	2006-04-12	-	-	2025-07-14
A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin	NCT02162407	Novo Nordisk A/S	user2@example.com	None	1999-10-31	1999-12-31	2000-12-31	-	-	2025-07-14
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	NCT00333151	Novo Nordisk A/S	user2@example.com	None	2006-05-31	2007-08-31	2008-08-31	-	-	2025-07-14
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes	NCT01562561	Novo Nordisk A/S	user2@example.com	None	2001-06-01	2002-12-20	2003-12-20	-	-	2025-07-14
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes	NCT01868568	Novo Nordisk A/S	user2@example.com	None	2008-04-30	2008-08-31	2009-08-31	-	-	2025-07-14
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)	NCT02005198	Novo Nordisk A/S	user2@example.com	None	2014-03-31	2015-12-31	2016-12-31	-	-	2025-07-14
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes	NCT01507311	Novo Nordisk A/S	user2@example.com	None	1999-09-30	1999-12-31	2000-12-31	-	-	2025-07-14
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects	NCT01916174	Novo Nordisk A/S	user2@example.com	None	2013-08-31	2013-11-30	2014-11-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance